Update on Hepatitis B Prevention
Journal: Annals of Internal Medicine (1987)

Diagnosis and Treatment1 September 1987Update on Hepatitis B PreventionRecommendations of the Immunization Practices Advisory CommitteeAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-107-2-353 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractAbstractSince plasma-derived hepatitis B vaccine was licensed for use in the United States in 1982, use of the vaccine in high-risk health care professions has been modest, despite widespread participation in the establishment of vaccination programs among these institutions. The incidence of hepatitis B virus infection has continued to increase in the past 5 years, presumably because vaccination programs have failed to reach the major risk groups of homosexual men, parenteral drug abusers, and heterosexually active persons with multiple sexual partners. Increased efforts toward the development of programs to vaccinate persons in all high-risk groups are recommended. The immunogenicity, safety, efficacy, and precautions involved in the use of a new recombinant DNA vaccine (licensed in 1986) are also discussed, and the need for booster doses of plasma-derived vaccine are evaluated.References1. . Recommendations for protection against viral hepatitis. MMWR. 1985;34:313-24,329-35. MedlineGoogle Scholar2. . Annual summary 1984: reported morbidity and mortality in the United States. MMWR. 1986;33(54):125. Google Scholar3. Hepatitis Surveillance Report No. 50. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, 1986:16-25. Google Scholar4. EMINIELLISMILLERMCALEERSCOLNICKGERETY ERWWER. Production and immunological analysis of recombinant hepatitis B vaccine. J Infect. 1986;13(suppl A):3-9. CrossrefMedlineGoogle Scholar5. ZAJACWESTMCALEERSCOLNICK BDWE. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect. 1986;13(suppl A):39-45. CrossrefMedlineGoogle Scholar6. STEVENSTAYLORTONG CPM. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257:2612-6. CrossrefMedlineGoogle Scholar7. FRANCISFEORINOMCDOUGAL DPS. The safety of hepatitis B vaccine: inactivation of the AIDS virus during routine vaccine manufacture. JAMA. 1986;256:869-72. CrossrefMedlineGoogle Scholar8. SZMUNESSSTEVENSHARLEY WCE. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833-41. CrossrefMedlineGoogle Scholar9. FRANCISHADLERTHOMPSON DSS. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982;97:362-6. LinkGoogle Scholar10. HADLERFRANCISMAYNARD SDJ. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209-14. CrossrefMedlineGoogle Scholar11. JILGSCHMIDTDEINHARDTZACHOVAL WMFR. Hepatitis B vaccination: how long does protection last [Letter]? Lancet. 1984;2:458. CrossrefMedlineGoogle Scholar12. COURSAGETYVONNETCHOTARD PBJ. Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet. 1986;2:1143-5. CrossrefMedlineGoogle Scholar13. STEVENSALTERTAYLOR CHP. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med. 1984;311:496-501. CrossrefMedlineGoogle Scholar14. MCLEANHILLEMANMCALEERBUYNAK AMWE. Summary of worldwide clinical experience with H-B-Vax (B, MSD). J Infect 1983;7(suppl):95-104. CrossrefMedlineGoogle Scholar15. DAVIDSONKRUGMAN MS. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect. 1986;13(suppl A):31-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: ▸From the Immunization Practices Advisory Committee, Centers for Disease Control; Atlanta, Georgia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byVirus-like particle-based vaccines against SARS-CoV-2Maternal-Fetal Infections with Human VirusesHepatitis por el virus BAfebrile Convulsion in an Adult after Recombinant Hepatitis B VaccinationMucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvantHepatitis B vaccine in hemodialysis patients with hepatitis C viral infectionAdult immunizationsControl and Prevention of Disease Transmission in Audiology PracticeRastreamento sorológico para hepatite B em profissionais de saúde na cidade de Goiânia - GoiásSimultaneous administration of Hepatitis B vaccine with other E.P.I. vaccinesHepatitis, HIV, and the dermatologist: A risk reviewFive-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responsesSexually transmitted diseases in children: herpes simplex virus infection, cytomegalovirus infection, hepatitis B virus infection and molluscum contagiosum.Viral Infections in the Dental Setting: Potential Effects on Pregnant HCWsSeroconversion by EMS Personnel Vaccinated with HBV Recombinant DNAThe Safety of Blood Components and DerivativesLong-term follow-up of hepatitis B vaccination in susceptible hospital personnelSEXUALLY TRANSMITTED VIRUSES OTHER THAN HIV AND PAPILLOMAVIRUSBooster response to recombinant yeast-derived hepatitis B vaccine in vaccinees whose anti-HBs responses were initially elicited by a plasma-derived vaccineVaccination of the Dialysis PatientMedical Schools and Immunization Policies: Missed Opportunities for Disease PreventionGregory A. Poland, MD, Kristin L. Nichol, MD, MPHResponse to hepatitis B immunization in children with hemophilia: Relationship to infection with human immunodeficiency virus type 1Immune Response to a Recombinant Hepatitis B Vaccine in Hemodialysis PatientsNosocomial infections in the pediatric patient: An updateYeast-derived hepatitis B vaccine in dental students. A three-year follow-up studyPassive-active immunoprophylaxis after percutaneous exposure to hepatitis B virusIs booster injection with hepatitis B vaccine necessary in healthy responders?Adult ImmunizationProtecting Health Care Workers from the Occupational Risk of DiseaseBriefly Noted 1 September 1987Volume 107, Issue 3Page: 353-357KeywordsAddictsBooster dosesDNA vaccinationHealth careHepatitis BHomosexualsSafetyVaccines ePublished: 1 December 2008 Issue Published: 1 September 1987 PDF downloadLoading ...